Certainly a bit happening out there. Fred Guerard’s recent presentation had a couple of interesting insights in that Opthea were actively working on a phase III trial for DME to start after the phase III readouts and the PCV subgroup was likely a $1 billion market in its own right. Notably this is the subset that had the greatest improvement in the phase IIb trial.
I have been thinking phase III results for Opt-302 could in fact deliver better results than the phase IIb trial. It is a known patients on VegF-A therapy continue to slowly relapse over time. Opt-302 in combination therapy in the phase IIb trial effectively stopped that decline for most patients. The phase IIb trial was over 6 months. If this effect is maintained for the full 12 months of the phase III trial then this effect may be magnified.
- Forums
- ASX - By Stock
- Ann: Security Class Reinstatement to Quotation- OPTOB
Certainly a bit happening out there. Fred Guerard’s recent...
-
- There are more pages in this discussion • 99 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OPT (ASX) to my watchlist
(20min delay)
|
|||||
Last
91.0¢ |
Change
0.035(4.00%) |
Mkt cap ! $1.120B |
Open | High | Low | Value | Volume |
90.0¢ | 94.0¢ | 87.5¢ | $6.570M | 7.220M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 29000 | 90.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
92.0¢ | 20922 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 29000 | 0.905 |
2 | 5251 | 0.900 |
2 | 41694 | 0.895 |
3 | 14298 | 0.890 |
2 | 33333 | 0.885 |
Price($) | Vol. | No. |
---|---|---|
0.940 | 41950 | 3 |
0.945 | 21000 | 1 |
0.950 | 15971 | 3 |
0.970 | 520 | 1 |
0.980 | 45502 | 6 |
Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |